与Helicobacter pylori在意大利南部的根除同时进行的四重治疗和四重治疗:来自随机临床试验的初步数据
Giuseppe Losurdo1, Antonia Valeria Borraccino1, Adriana Aloisio1
1Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.
Antibiotics (Basel, Switzerland)
|April 26, 2024
概括
同时治疗 (CT) 和芝麻四倍疗法 (BQT) 显示出类似的有效性和安全性,用于根除Helicobacter pylori (H. pylori) 在一个具有高克拉素耐药性的地区. 这两种治疗都是H. pylori感染的可行的一线治疗方案.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 高度的克拉里素耐药性需要使用替代的H. pylori根除策略.
- 同时治疗 (CT) 和木四重治疗 (BQT) 是在这些地区推的第一线治疗.
- 随机对照试验对于比较这些治疗方案的有效性和安全性至关重要.
研究的目的:
- 为了比较CT与BQT作为一线H. pylori根除疗法的疗效和安全性.
- 评估接受CT或BQT的患者的治疗成功率和不良事件.
- 提供基于证据的建议,以治疗H. pylori在高克拉里素耐药性地区.
主要方法:
- 一项随机对照试验,涉及通过尿素呼吸试验和组织学诊断出H. pylori的患者.
- 患者接受了为期10天的CT (阿莫西西林,明素,美特罗尼达) 或为期10天的BQT (Pylera).
- 两种疗法均与潘托普拉联合使用;由于没有脱离,进行了治疗意向分析.
主要成果:
- 根除H. pylori的成功率为CT的95.6%,BQT的100% (p=0.56).
- 23.9%的CT患者和31.6%的BQT患者报告了不良事件 (p=0.47).
- 常见的副作用包括腹痛和腹,两组之间没有显著差异.
结论:
- CT和BQT在意大利南部的H. pylori根除中显示出相似的疗效和安全性,该地区的克拉里素耐药性很高.
- 这两种方案都是有效的第一线治疗,提供了成功的H. pylori根除,并具有可控的副作用.
- 这些发现支持在类似的流行病学环境中使用CT或BQT.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
379
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
379
01:26Peptic Ulcer Disease IV: Management
89
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
89
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
115
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
115
01:23Gastritis III: Clinical Manifestations and Management
232
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
232
01:21Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
01:30Peptic Ulcer Disease I: Introduction
165
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
165